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Africa, a national laboratory for drug quality was built and well
equipped.
Global Antibiotic resistance partnership (GARP) provided a
framework to bring together many of the leaders of the programs
that form components of a national antibiotic resistance plan. The
GARP Mozambique working group brought them together with
a shared purpose, including both veterinary and human health
specialists including civil society ou consumer association. The
development of the situation analysiswas key to creating anational
focus on antibiotic resistance,whichhas resulted in appointment of
a focal person at the National Directorate of Health Care. It has also
sparked collaboration of the Ministries of Health and Agriculture, a
greater interest among students and researchers to ﬁll information
gaps, the beginning of AMR surveillance in three regions, and the
development of a National Action Plan on antibiotic resistance. The
seeds of this movement already existed in Mozambique and the
development would have taken place eventually, but GARP accel-
erated progress and provided signiﬁcant support as Mozambique
has become part of a growing network.
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Abstract: TheGlobalAntibiotic ResistancePartnership (GARP) is
a project started by the Center for Disease Dynamics, Economics &
Policy in 2008, with funding from the Bill & Melinda Gates Founda-
tion. GARP now includes eight low- and middle-income countries,
including the ones represented in this session, and is set to expand
further in Africa and Asia. The GARP model involves bringing
together professionals already expert in aspects of antimicrobial
resistance (AMR), and covering both human and animal antibi-
otic use and resistance in what we have called “working groups.”
Although the working groups are free standing and uncompen-
sated, where possible, they include representation from Ministries
of Health and Agriculture. These groups become a national brain
trust on AMR, working collaboratively with government. We have
learned that this is a way for low-resource countries to start on
an evidence-based path to national AMR plans without an initial
government investment. A key tool that we have required working
groups to produce is a situation analysis that includes all available
(published and unpublished) information on antibiotic resistance
in humans and animals in the country, enriched by contextual
information, such as the burden of antibiotic-treatable disease in
the country, the supply chain for antibiotics, access to antibiotics
among the population, etc. Important to completing the situation
analysis has been the requirement of a paid working group coor-
dinator, in all cases a young professional, which brings the added
beneﬁt of capacity building. Building up to national AMRplansmay
take several years in countries that have not started the process,
but the global imperative now evident may help to shorten that
timeline. The GARP process of relying on local leadership through
a working group is one model that has been successful and is avail-
able for other countries to borrow and improve upon.
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